Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for RedHill Biopharma (RDHL) over the last 10 years, with Q2 2025 value amounting to $10.7 million.

  • RedHill Biopharma's Accumulated Expenses rose 16978.04% to $10.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.7 million, marking a year-over-year increase of 16978.04%. This contributed to the annual value of $10.0 million for FY2024, which is 11761.76% up from last year.
  • Per RedHill Biopharma's latest filing, its Accumulated Expenses stood at $10.7 million for Q2 2025, which was up 16978.04% from $10.0 million recorded in Q4 2024.
  • RedHill Biopharma's Accumulated Expenses' 5-year high stood at $25.4 million during Q1 2021, with a 5-year trough of $4.0 million in Q2 2024.
  • For the 5-year period, RedHill Biopharma's Accumulated Expenses averaged around $16.2 million, with its median value being $19.1 million (2022).
  • In the last 5 years, RedHill Biopharma's Accumulated Expenses tumbled by 7441.64% in 2023 and then surged by 16978.04% in 2025.
  • RedHill Biopharma's Accumulated Expenses (Quarter) stood at $20.9 million in 2021, then decreased by 14.1% to $17.9 million in 2022, then crashed by 74.42% to $4.6 million in 2023, then soared by 117.62% to $10.0 million in 2024, then grew by 6.93% to $10.7 million in 2025.
  • Its Accumulated Expenses was $10.7 million in Q2 2025, compared to $10.0 million in Q4 2024 and $4.0 million in Q2 2024.